Shanghai Fosun Pharmaceutical (02196) reported its first quarter performance, with a net profit attributable to the parent of 765 million yuan, an increase of 25.42% year-on-year.
Fosun Pharma (02196) released its first quarter performance for 2025, with the group achieving operating income of 9.42 billion yuan...
Shanghai Fosun Pharmaceutical (02196) released its first quarter performance for 2025, the group achieved operating income of 9.42 billion yuan, a decrease of 7.26% year-on-year; net profit attributable to shareholders of the listed company was 765 million yuan, an increase of 25.42% year-on-year; basic earnings per share was 0.29 yuan.
Related Articles
China Railway Construction Corporation (01186) appoints Ernst & Young Hua Ming as the auditing agency for the year 2025.
China Railway Construction Corporation's subsidiary company has won the bid for the early construction section of the Zhongjihu Railway Project, with a contract amount of approximately 25.87 billion yuan.
UNI HEALTH (02211) plans to "10-for-1" share consolidation.
China Railway Construction Corporation (01186) appoints Ernst & Young Hua Ming as the auditing agency for the year 2025.
China Railway Construction Corporation's subsidiary company has won the bid for the early construction section of the Zhongjihu Railway Project, with a contract amount of approximately 25.87 billion yuan.
UNI HEALTH (02211) plans to "10-for-1" share consolidation.
RECOMMEND
From AI chatting to online shopping, OpenAI is striving to make ChatGPT the "universal application" of the AI era.
29/04/2025
Deutsche Bank warns: Overseas investors continue to withdraw from US assets, challenging the status of the US dollar.
29/04/2025
Analyst: Gold's peak risk intensifies, silver welcomes breakthrough opportunities.
28/04/2025
